Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

NOVO: Financial report for 1 January 2024 to 30 Juli 24


121672 ProInvestorNEWS 7/8 2024 07:39
Oversigt

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024

Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion.

Sales in North America Operations increased by 36% in Danish kroner (36% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 9% in Danish kroner (11% at CER).
Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 125.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 32% in Danish kroner (32% at CER) and Obesity care growing by 37% in Danish kroner to DKK 24.9 billion (37% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER).
Within R&D, Novo Nordisk successfully completed the phase 3 FRONTIER 2 trial with Mim8, where once-weekly and once-monthly Mim8 demonstrated superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A. In June 2024, Novo Nordisk announced that the ocedurenone CLARION-CKD phase 3 trial was stopped, as ocedurenone failed to meet the primary endpoint.
Also within R&D, Novo Nordisk received a Complete Response Letter from the Food and Drug Administration (FDA) for insulin icodec in July. In Obesity care, Novo Nordisk received a positive CHMP opinion, based on the SELECT trial, for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events in the EU.
For the 2024 outlook, sales growth is now expected to be 22-28% at CER, and operating profit growth is now expected to be 20-28% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for both sales and operating profit.

PROFIT AND LOSS H1 2024 H1 2023 Growth
as reported Growth
at CER*
DKK million
Net sales 133,409 107,667 24% 25%
Operating profit 57,780 48,895 18% 19%

Net profit 45,457 39,242 16% N/A
Diluted earnings per share (in DKK) 10.17 8.71 17% N/A
* CER: Constant exchange rates (average 2023).

Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first half of 2024, which has enabled us to raise the outlook for the full year. The growth is driven by the increased demand for our GLP-1-based diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments. Within R&D, we are very pleased with the first phase 3 trial results with Mim8 and its potential for people living with haemophilia A, and with the recent recommendation for a label extension for cardiovascular risk reduction for Wegovy® in the EU."

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown

+45 3079 9289
abmo@novonordisk.com Liz Skrbkova (US)

+1 609 917 0632
lzsk@novonordisk.com




7/8 2024 08:05 TOPspiller 1121674



Bom bom bom.... Hvordan kommer dagen til at starte for Novo?

link til nedestående:https://www.euroinvestor.dk/nyheder/novo-nordisk-opjusterer


Til gengæld nedpræciserer Novo Nordisk sine forventinger til driftsresultatet for helåret 2024. Dermed venter medicinalmastodonten nu en vækst i driftsresultatet på 20-28 pct. mod tidligere 22-30 pct.

Zoomer man ind på det forgangne kvartal, misser medicinalkæmpen dog på et par nøgletal, hvis man tager udgangspunkt i analytikernes forventninger.

Omsætningen lyder på 68,1 mia. kr., hvilket er mindre end de på forhånd ventede 68,7 mia. kr. ifølge konsensusestimater fra finanstjenesten Bloomberg.

Driftsresultatet, EBIT, der er et udtryk for, hvor effektiv en virksomhed er til at drive sin forretning, lander på 25,9 mia. kr. mod analytikernes ventede 27,3 mia. kr.

På bundlinjen ligger der 20,1 mia. kr. Det er også mindre end de ventede 22,6 mia. kr.

----

Opjurstering men skuffer vel på en del områder.



7/8 2024 08:58 ProInvestorNEWS 0121682



Novo Nordisk leverer den ventede opjustering https://proinvestor.com/boards/121675/



TRÅDOVERSIGT